Wird geladen...
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
In the last few years, the treatment of patients with non-small cell lung cancer (NSCLC) has impressively benefitted from immunotherapy, in particular from the inhibition of immune checkpoints such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1). However, despite the sig...
Gespeichert in:
| Veröffentlicht in: | J Thorac Dis |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
AME Publishing Company
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6353746/ https://ncbi.nlm.nih.gov/pubmed/30775030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.11.102 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|